

Case #PC31283(S03376)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
Fede et al

GROUP ART UNIT: 1617

SERIAL NO.: 09/941,206

EXAMINER: J. Kim

FILED: 08/28/2001

DATE: August 18, 2005

TITLE: USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE
COGNITIVE FUNCTION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner for Patents
Alexandria, VA 22313

Sir:


This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Christopher W. Slavinsky
Attorney for Applicants
Registration No. 54,456
Tel: 314-274-7008

Pharmacia Corporation
Of Pfizer Inc
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63306



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.:PC31283(3376)	APPLICATION NO.: 09/941,206
	INVENTOR: Fedde, et al.	
	Filed: 8/28/2001	Group: 1617

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	09/518855		Alexander et al			03/03/2000

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	2	Fogari et al, Drugs Aging, 21 (6), 377-393, 2004
	3	Croom et al, Am J Cardiovasc Drugs, 5(1), 51-69, 2005
	4	Rychlik et al, Expert Rev Pharmacoeconomics Outcomes Res, 5(3), 277-286,2005
	5	Hobbs et al, American Journal of Therapeutics, 11, 467-472, 2004
	6	Sosin et al, Current Pharmaceutical Design, 10, 3569-3577, 2004
	7	Mejhert et al, Heart, 90, 1010-1015, 2004
	8	Akosah et al, Dis Manage Health Outcomes, 12(4), 221-227, 2004

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	